PHBID (Neorich Biopharma Tech Co) Change In Receivables: $0.00 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neorich Biopharma Tech Co Change In Receivables?

Neorich Biopharma Tech Co PHBID -44.44% Change In Receivables is $0.00 Mil as of Jun. 2023.

Neorich Biopharma Tech Co's change in receivables for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Neorich Biopharma Tech Co's Accounts Receivable stayed the same from Mar. 2023 to Jun. 2023 .

Neorich Biopharma Tech Co's change in receivables for the fiscal year that ended in Sep. 2022 was $0.00 Mil. It means Neorich Biopharma Tech Co's Accounts Receivable stayed the same from Sep. 2021 to Sep. 2022 .

Neorich Biopharma Tech Co's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Neorich Biopharma Tech Co's Days Sales Outstanding for the three months ended in Jun. 2023 was 91.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Neorich Biopharma Tech Co's liquidation value for the three months ended in Jun. 2023 was $-2.28 Mil.

Neorich Biopharma Tech Co  (OTCPK:PHBID) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Neorich Biopharma Tech Co's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.001/0.001*91
=91.25

2. In Ben Graham's calculation of liquidation value, Neorich Biopharma Tech Co's accounts receivable are only considered to be worth 75% of book value:

Neorich Biopharma Tech Co's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.005-2.291+0.75 * 0.001+0.5 * 0.009
=-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neorich Biopharma Tech Co Change In Receivables Related Terms

Neorich Biopharma Tech Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Neorich Biopharma Tech Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neorich Biopharma Tech Co Change In Receivables Chart

Neorich Biopharma Tech Co Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Change In Receivables
Get a 7-Day Free Trial -0.03 0.02 0.01 0.00 0.00

Neorich Biopharma Tech Co Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neorich Biopharma Tech Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Neorich Biopharma Tech Co (PHBID) has a Change In Receivables of $0.00 Mil as of Jun. 2023. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's Change In Receivables too high?
Neorich Biopharma Tech Co's current Change In Receivables is $0.00 Mil.
How does Neorich Biopharma Tech Co's Change In Receivables compare to DVLP and CSTF?
Neorich Biopharma Tech Co's Change In Receivables of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Neorich Biopharma Tech Co and its competitors. Neorich Biopharma Tech Co's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current Change In Receivables is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neorich Biopharma Tech Co Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.